Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28825749 | 0.95 | HPGD (0.55) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3900458 | 0.87 | CASP3 (0.52) | SMN1; SMN2MEN1KMT2AMAPTGAA | |
| SCHEMBL1415624 | 0.82 | CASP3 (0.45) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1415828 | 0.82 | TDP1 (0.48) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1415410 | 0.81 | AKR1C3 (0.45) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1415827 | 0.81 | AKR1C3 (0.45) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1415497 | 0.81 | DHODH (0.44) | MEN1KMT2AHPGDNPC1MAPT | |
| SCHEMBL1416251 | 0.81 | SMN1; SMN2 (0.54) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12392802 | 0.77 | ACHE (0.43) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7621011 | 0.76 | MAPT (0.49) | AKR1C3AKR1C2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1031615-B1 | Aqueous process for the preparation of linear quinacridones having a reduced particle size | CIBA SC HOLDING AG (CH) | 2003-07-23 | — | — | EP | claimed |
| EP-1031615-A2 | Aqueous process for the preparation of linear quinacridones having a reduced particle size | Ciba SC Holding AG (CH) | 2000-08-30 | — | — | EP | claimed |
| EP-1399742-B1 | QUINACRIDONE LABELLING REAGENTS FOR FLUORESCENCE DETECTION OF BIOLOGICAL MATERIALS | GE HEALTHCARE UK LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-7335771-B2 | Quinacridone derivatives as labelling reagents for fluorescence detection of biological materials | GE HEALTHCARE UK LIMITED (GB) | 2008-02-26 | — | — | US | disclosed |
| US-20040171014-A1 | Quinacridone derivatives as labelling reagents for flurescence detection of bilogical materials | TTP LABTECH LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1399742-A2 | QUINACRIDONE LABELLING REAGENTS FOR FLUORESCENCE DETECTION OF BIOLOGICAL MATERIALS | Amersham Biosciences UK Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| EP-1031615-B1 | Aqueous process for the preparation of linear quinacridones having a reduced particle size | CIBA SC HOLDING AG (CH) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002099432-A2 | QUINACRIDONE LABELLING REAGENTS FOR FLUORESCENCE DETECTION OF BIOLOGICAL MATERIALS | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2002-12-12 | — | — | WO | disclosed |
| EP-1031615-A2 | Aqueous process for the preparation of linear quinacridones having a reduced particle size | Ciba SC Holding AG (CH) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171014-A1 | Quinacridone derivatives as labelling reagents for flurescence detection of bilogical materials | Q6ZSR9, MPHOSPH6, NQO2 | AKR1C3 1652/4885AKR1C2 2174/4885SMN1; SMN2 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.